<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0410234292
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Pantrox
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PANTOPRAZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gastro-resistant tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        112.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hetero Labs Limited Unit &#x2013; V" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hetero Labs Limited Unit – V
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pantrox contains the active substance pantoprazole. Pantrox is a selective &ldquo;proton pump inhibitor&rdquo;, a medicine which reduces the amount of acid produced in your stomach. It is used for treating acid- related diseases of the stomach and intestine.</p><p>Pantrox is used to treat adults and adolescents 12 years of age and above for</p><p>&bull;&nbsp; Reflux oesophagitis. An inflammation of your oesophagus (the tube which connects your throat to your stomach) accompanied by the regurgitation of stomach acid.</p><p>Pantrox is used to treat adults for</p><p>&bull;&nbsp; An infection with a bacterium called Helicobacter pylori inpatients with duodenal ulcers and stomach ulcers in combination with two antibiotics (eradication therapy).The aim is to get rid of the bacteria and so reduce the likelihood of these ulcers returning.</p><p>&bull;&nbsp; Stomach and duodenal ulcers.</p><p dir="RTL">Zollinger-Ellison-Syndrome and other conditions producing too much acid in the stomach</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take Pantrox</p><p>- If you are allergic to pantoprazole or to any of the other ingredients of this medicine (listed in section 6).</p><p>- If you are allergic to medicines containing other proton pump inhibitors.</p><p>Warnings and precautions</p><p>- If you have severe liver problems. Please tell your doctor if you ever had problems with your liver in the past. He will check your liver enzymes more frequently, especially when you are taking Pantrox as a long-term treatment. In the case of a rise of liver enzymes the treatment should be stopped.</p><p>- If you have reduced body stores or risk factors for reduced vitamin B12 and receive long-term treatment with pantoprazole. As with all acid reducing agents, pantoprazole may lead to a reduced absorption of vitamin B12.</p><p>- If you are taking HIV protease inhibitors such as atazanavir (for the treatment of HIV-infection) at the same time as pantoprazole, ask your doctor for specific advice.</p><p>- If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with [Pantrox]. Remember to also mention any other ill-effects like pain in your joints.</p><p>- If you are due to have a specific blood test (Chromogranin A)</p><p>- Taking a proton pump inhibitor like pantoprazole, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).</p><p>- If you are on Pantoprazole for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness or increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood.</p><p>Your doctor may decide to perform regular blood tests to monitor your levels of magnesium. Tell your doctor immediately, before or after taking this medicine, if you notice any of the following symptoms, which could be a sign of another, more serious, disease:</p><p>- an unintentional loss of weight</p><p>- vomiting, particularly if repeated</p><p>- vomiting blood; this may appear as dark coffee grounds in your vomit</p><p>- you notice blood in your stools; which may be black or tarry in appearance</p><p>- difficulty in swallowing or pain when swallowing</p><p>- you look pale and feel weak (anaemia)</p><p>- chest pain</p><p>- severe and/or persistent diarrhoea, because this medicine has been associated with a small increase in infectious diarrhoea.</p><p>Your doctor may decide that you need some tests to rule out malignant disease because pantoprazole also alleviates the symptoms of cancer and could cause delay in diagnosing it. If your symptoms continue in spite of your treatment, further investigations will be considered.</p><p>If you take Pantrox on a long-term basis (longer than 1 year) your doctor will probably keep you under regular surveillance. You should report any new and exceptional symptoms and circumstances whenever you see your doctor.</p><p>Children and adolescents</p><p>Pantrox is not recommended for use in children as it has not been proven to work in children below 12 years of age.</p><p>Other medicines and Pantrox</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.</p><p>This is because Pantrox may influence the effectiveness of other medicines, so tell your doctor if you are taking:</p><p>- Medicines such as ketoconazole, itraconazole and posaconazole (used to treat fungal infections) or erlotinib (used for certain types of cancer) because Pantrox may stop these and other medicines from working properly.</p><p>- Warfarin and phenprocoumon, which affect the thickening, or thinning of the blood. You may need further checks.</p><p>- Medicines used to treat HIV-infection, such as atazanavir.</p><p>- Methotrexate (used to treat rheumatoid arthritis, psoriasis, and cancer) &ndash; if you are taking methotrexate your doctor may temporarily stop your Pantrox treatment because pantoprazole can increase levels of methotrexate in the blood.</p><p>- Fluvoxamine (used to treat depression and other psychiatric diseases) &ndash; if you are taking fluvoxamine your doctor may reduce the dose.</p><p>- Rifampicin (used to treat infections).</p><p>- St John&rsquo;s wort (Hypericum perforatum) (used to treat mild depression).</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>Pregnancy and breast-feeding</p><p>There are no adequate data from the use of pantoprazole in pregnant women. Excretion into human milk has been reported.</p><p>If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>You should use this medicine, only if your doctor considers the benefit for you greater than the potential risk for your unborn child or baby.</p><p>Driving and using machines</p><p>Pantoprazole has no or negligible influence on the ability to drive and use machines.</p><p>If you experience side effects like dizziness or disturbed vision, you should not drive or operate machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Method of administration</p><p>Take the tablets 1 hour before a meal without chewing or breaking them and swallow them whole with some water.</p><p>The recommended dose is:</p><p>Adults and adolescents 12 years of age and above</p><p>-To treat reflux oesophagitis</p><p>The usual dose is one tablet a day. Your doctor may tell you to increase to 2 tablets daily. The treatment period for reflux oesophagitis is usually between 4 and 8weeks. Your doctor will tell you how long to take your medicine.</p><p>Adults</p><p>- For the treatment of an infection with a bacterium called Helicobacter pylori in patients with duodenal ulcers and stomach ulcers in combination with two antibiotics (Eradication therapy).One tablet, two times a day plus two antibiotic tablets of either amoxicillin, clarithromycin and metronidazole (or tinidazole), each to be taken two times a day with your pantoprazole tablet. Take the first pantoprazole tablet 1 hour before breakfast and the second pantoprazole tablet 1 hour before your evening meal. Follow your doctor&rsquo;s instructions and make sure you read the package leaflets for these antibiotics. The usual treatment period is one to two weeks.</p><p>- For the treatment of stomach and duodenal ulcers. The usual dose is one tablet a day. After consultation with your doctor, the dose may be doubled. Your doctor will tell you how long to take your medicine. The treatment period for stomach ulcers is usually between 4 and 8 weeks. The treatment period for duodenal ulcers is usually between 2 and 4weeks.</p><p>- For the long-term treatment of Zollinger-Ellison-Syndrome and of other conditions in which too much stomach acid is produced. The recommended starting dose is usually two tablets a day. Take the two tablets 1 hour before a meal. Your doctor may later adjust the dose, depending on the amount of stomach acid you produce. If prescribed more than two tablets a day, the tablets should be taken twice daily. If your doctor prescribes a daily dose of more than four tablets a day, you will be told exactly when to stop taking the medicine.</p><p>Patients with kidney problems</p><p>If you have kidney problems, you should not take Pantrox for eradication of Helicobacter pylori.</p><p>Patients with liver problems</p><p>If you suffer from severe liver problems, you should not take more than one tablet 20 mg pantoprazole a day (for this purpose tablets containing 20 mg pantoprazole are available). If you suffer from moderate or severe liver problems, you should not take Pantrox for eradication of Helicobacter pylori.</p><p>Use in children and adolescents</p><p>These tablets are not recommended for use in children below 12years.</p><p>If you take more Pantrox than you should</p><p>You should Consult your doctor or pharmacist. There are no known symptoms of over dose.</p><p>If you forget to take Pantrox</p><p>Do not take a double dose to make up for a forgotten dose. Take your next, normal dose at the usual time.</p><p>If you stop taking Pantrox</p><p>Do not stop taking these tablets without first talking to your doctor or pharmacist.</p><p>If you have any further questions about the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If you get any of the following side effects, stop taking these tablets and tell your doctor immediately, or contact the casualty department at your nearest hospital:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serious allergic reactions (frequency rare: </strong>may affect up to 1 in 1,000 people<strong>): </strong>swelling of the tongue and/or throat, difficulty in swallowing, hives (nettle rash), difficulties in breathing,</p><p>allergic facial swelling (Quincke&rsquo;s oedema / angioedema), severe dizziness with very fast heartbeat and heavy sweating.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Serious skin conditions (frequency not known: </strong>frequency cannot be estimated from the available data<strong>): </strong>blistering of the skin and rapid deterioration of your general condition, erosion (including slight bleeding) of eyes, nose, mouth/lips or genitals (Stevens-Johnson-Syndrome, Lyell-Syndrome, Erythema multiforme), and sensitivity to light.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other serious conditions (frequency not known: </strong>frequency cannot be estimated from the available data<strong>): </strong>yellowing of the skin or whites of the eyes (severe damage to liver cells, jaundice) or fever, rash, and enlarged kidneys sometimes with painful urination, and lower back pain (serious inflammation of the kidneys), possibly leading to kidney failure.</p><p>Other side effects are:</p><p>-&nbsp; <strong>Common </strong>(may affect up to 1 in 10 people) Benign polyps in the stomach.</p><p>-&nbsp; <strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><p>Headache; dizziness; diarrhoea; feeling sick, vomiting; bloating and flatulence (wind); constipation; dry mouth; abdominal pain and discomfort; skin rash, exanthema, eruption; itching; feeling weak, exhausted or generally unwell; sleep disorders; fracture in the hip, wrist or spine.</p><p>-&nbsp; <strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>Distortion or complete lack of the sense of taste; disturbances in vision such as blurred vision; hives, pain in the joints; muscle pains; weight changes; raised body temperature; high fever; swelling of the extremities (peripheral oedema); allergic reactions; depression; breast enlargement in males.</p><p>-&nbsp; <strong>Very Rare </strong>(may affect up to1 in 10,000 people) Disorientation.</p><p>-&nbsp; <strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>Hallucination, confusion (especially in patients with a history of these symptoms); decreased sodium level in blood, decreased magnesium level in blood (see section 2), feeling of tingling, prickling, pins and needles, burning sensation or numbness, rash, possibly with pain in the joints.</p><p>Side effects identified through blood tests:</p><p>-&nbsp; <strong>Uncommon </strong>(may affect up to 1 in 100 people) an increase in liver enzymes.</p><p>-&nbsp; <strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><p>an increase in bilirubin; increased fat levels in blood; sharp drop in circulating granular white blood cells, associated with high fever.</p><p>-&nbsp; <strong>Very Rare </strong>(may affect up to 1 in 10,000 people) a reduction in the number of blood platelets, which may cause you to bleed or bruise more than normal; a reduction in the number of white blood cells, which may lead to more frequent infections; coexisting abnormal reduction in the number of red and white blood cells, as well as platelets.</p><p><u><strong>Reporting of side effects</strong></u></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, health care provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the pack after EXP. The expiry date refers to the last day of the month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp; What Pantrox contains Pantrox 20</p><p>The active substance is Pantoprazole Sodium Sesquihydrate.</p><p>Each gastro resistant tablet contains Pantoprazole sodium sesquihydrate Ph. Eur equivalent to 20mg of Pantoprazole.</p><p>The other ingredients are: Lactose Monohydrate, Hydroxypropyl cellulose, Calcium Stearate, Sodium carbonate anhydrous, Sodium lauryl sulphate, Hypromellose, Ferric oxide yellow, Propylene glycol, Titanium dioxide, Methacrylic Acid and Ethyl Acrylate Copolymer Dispersion, Triethyl citrate, Polysorbate80, Carnauba WAX.</p><p>Imprinting Ink Composition: Shellac Glaze~45% (20% Esterified) in Ethanol, Isopropyl Alcohol, Ferrosoferric Oxide/Black Iron Oxide, N-Butyl Alcohol, Propylene Glycol, Ammonium Hydroxide 28%.</p><p>Pantrox 40</p><p>The active substance is Pantoprazole Sodium Sesquihydrate.</p><p>Each gastro resistant tablet contains Pantoprazole sodium sesquihydrate Ph.Eur equivalent to 40mg of Pantoprazole.</p><p>The other ingredients are: Lactose Monohydrate, Hydroxypropyl cellulose, Calcium Stearate, Sodium carbonate anhydrous, Sodium lauryl sulphate, Hypromellose, Ferric oxide yellow, Propylene glycol, Titanium dioxide, Methacrylic Acid and Ethyl Acrylate Copolymer Dispersion, Triethyl citrate, Polysorbate80, Carnauba WAX.</p><p>Imprinting Ink Composition: Shellac Glaze~45% (20% Esterified) in Ethanol, Isopropyl Alcohol, Ferrosoferric Oxide/Black Iron Oxide, N-Butyl Alcohol, Propylene Glycol, Ammonium Hydroxide 28%.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pantrox 20
Yellow to pale yellow, oval, biconvex, gastro resistant tablets imprinted 'H125' on one side with black ink and plain on the other side.
Pantrox 40
Yellow to pale yellow, oval, biconvex, gastro resistant tablets imprinted 'H126' on one side with black ink and plain on the other side.
How supplied:
Pantrox 20 mg tablets are supplied in Blister Pack.
Box of 20’s, 30’s and 60’s blistered tablets (2x10’s, 3x10’s and 6x10’s). Pantrox 40 mg tablets are supplied in Blister Pack.
Box of 20’s, 30’s and 60’s blistered tablets (2x10’s, 3x10’s and 6x10’s).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Saudi Amarox Industrial Company</strong></p><p>Al Jamiah Street, Al Malaz District</p><p>Riyadh 12629, Saudi Arabia</p><p>Tel &amp; Fax: +966 11 226 8850&nbsp;</p><p><u><strong>Manufacturer</strong></u></p><p>Hetero Labs Limited Unit V &ndash; India</p><p><strong>This leaflet was last revised in October 2023 , Version 1</strong>.</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia<em>:</em></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>-&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>Please update the website link in the illustrator without changing place</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States: </em></strong></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                October 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي بانتروكس على المادة الفعالة بانتوبرازول. &nbsp;بانتوبرازول هو مثبط انتقائي لمضخة البروتون وهو دواء يقلل من كمية الحمض المنتجة في معدتك. يتم استخدامه لعلاج أمراض المعدة والأمعاء المرتبطة بفرط إفراز الحمض.</p><p dir="RTL">يستخدم بانتروكس للبالغين والمراهقين بعمر 12 سنة وما فوق لعلاج:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كعلاج لالتهاب المريء الارتجاعي (التهاب المريء المصحوب بارتجاع حمض المعدة).</p><p dir="RTL">يستخدم بانتروكس لعلاج البالغين من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;العدوى ببكتيريا تسمى هيليكوباكتر بيلوري لمرضى التنويم في المستشفى الذين يعانون من قرحة الاثني عشر وقرحة المعدة بالاشتراك مع اثنين من المضادات الحيوية (علاج الاستئصال). الهدف هو التخلص من البكتيريا وبالتالي تقليل احتمالية عودة هذه القرحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;قرحة المعدة والاثني عشر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة زولينجر إليسون وغيرها من الحالات التي تنتج الكثير من الحمض في المعدة..</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم بانتروكس</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كان لديك حساسية من بانتوبرازول أو لأي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تعاني من حساسية تجاه الأدوية التي تحتوي على مثبطات مضخة البروتون الأخرى.</p><p dir="RTL"><strong>التحذيرات والإحتياطات</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل خطيرة في الكبد. من فضلك أخبر طبيبك إذا كنت تعاني من مشاكل مع الكبد في الماضي. سيقوم الطبيب بفحص إنزيمات الكبد بشكل متكرر خاصة عندما تكون كذلك.</p><p dir="RTL">استخدام بانتروكس كعلاج طويل الأمد. في حالة إرتفاع إنزيمات الكبد يجب إيقاف العلاج.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من انخفاض مخزون الجسم أو وجود عوامل خطر لخفض فيتامين ب 12 وتلقي علاج طويل الأمد مع بانتروكس. كما هو الحال مع جميع عوامل تقليل الحموضة قد يؤدي بانتروكس إلى انخفاض امتصاص فيتامين ب 12.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تتناول مثبطات إنزيم البروتياز لفيروس نقص المناعة البشرية مثل أتازانافير (لعلاج عدوى فيروس نقص المناعة البشرية) في نفس الوقت مع عقار بانتروكس ، فاسأل طبيبك عن نصائح محددة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;قد يؤدي تناول مثبطات مضخة البروتون مثل بانتروكس ، خاصة على مدى أكثر من عام ، إلى زيادة طفيفة في خطر إصابتك بكسر في الورك أو الرسغ أو العمود الفقري. أخبر طبيبك إذا كنت تعاني من هشاشة العظام أو إذا كنت تتناول الكورتيكوستيرويدات (التي يمكن أن تزيد من خطر الإصابة بهشاشة العظام).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت تتناول عقار بانتروكس لمدة تزيد عن ثلاثة أشهر ، فمن المحتمل أن تنخفض مستويات الماغنيسيوم في الدم. يمكن أن يُنظر إلى المستويات المنخفضة من الماغنيسيوم على أنها إرهاق أو تقلصات عضلية لا إرادية ، أو ارتباك ، أو تشنجات ، أو دوار ، أو زيادة معدل ضربات القلب. إذا ظهرت لديك أي من هذه الأعراض فيرجى إخبار طبيبك على الفور. يمكن أن يؤدي انخفاض مستويات المغنيسيوم أيضًا إلى انخفاض مستويات البوتاسيوم أو الكالسيوم في الدم. قد يقرر طبيبك إجراء فحوصات دم منتظمة لمراقبة مستويات الماغنيسيوم لديك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا عانيت من قبل من رد فعل تحسسي جلدي بعد العلاج بدواء مشابه للبانتروكس والذي يقلل من حموضة المعدة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا أصبت بطفح جلدي على جلدك ، خاصة في المناطق المعرضة للشمس ، أخبر طبيبك بأسرع ما يمكن ، حيث قد تحتاج إلى إيقاف العلاج باستخدام البانتروكس. تذكر أيضًا أن تذكر أي آثار سيئة أخرى مثل ألم المفاصل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كان من المقرر إجراء فحص دم محدد (كروموجرانين أ).</p><p dir="RTL"><strong>أخبر طبيبك على الفور</strong> قبل أو بعد تناول هذا الدواء ، إذا لاحظت أيًا من الأعراض التالية ، والتي قد تكون علامة على مرض آخر أكثر خطورة:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;فقدان الوزن غير المقصود</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التقيؤ خاصة إذا تكرر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تقيؤ الدم؛ قد يظهر هذا على شكل بقايا داكنة في القيء</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;لاحظت وجود دم في برازك. الذي قد يكون أسود أو قطراني المظهر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;صعوبة في البلع أو ألم عند البلع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تبدو شاحبًا وتشعر بالضعف (فقر الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ألم صدر</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الإسهال الشديد و / أو المستمر ، لأن هذا الدواء قد ارتبط بزيادة طفيفة في الإسهال المعدي.</p><p dir="RTL">قد يقرر طبيبك أنك بحاجة إلى بعض الاختبارات لاستبعاد مرض خبيث لأن عقار بانتروكس يخفف أيضًا من أعراض السرطان ويمكن أن يتسبب في تأخير تشخيصه. إذا استمرت الأعراض الخاصة بك على الرغم من العلاج فسيتم النظر في مزيد من الفحوصات.</p><p dir="RTL">إذا كنت تتناول عقار بانتروكس على المدى الطويل (أطول من سنة واحدة) فمن المحتمل أن يبقيك طبيبك تحت المراقبة المنتظمة. يجب عليك الإبلاغ عن أي أعراض وظروف جديدة واستثنائية كلما رأيت طبيبك.</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُنصح باستخدام عقار بانتروكس في الأطفال حيث لم يثبت فعاليته في الأطفال دون سن 12 عامًا.</p><p dir="RTL"><strong>الأدوية الأخرى والبانتروكس</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL">هذا لأن عقار بانتروكس قد يؤثر على فعالية الأدوية الأخرى ، لذا أخبر طبيبك إذا كنت تتناول:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;أدوية مثل كيتوكونازول ، إيتراكونازول وبوساكونازول (تستخدم لعلاج الالتهابات الفطرية) أو إرلوتينيب (يستخدم لأنواع معينة من السرطان) لأن البانتروكس قد يوقف هذه الأدوية وغيرها عن العمل بشكل صحيح.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الوارفارين والفينبروكومون ، اللذان يؤثران على سماكة أو ترقق الدم. قد تحتاج إلى مزيد من الفحوصات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الأدوية المستخدمة لعلاج الإصابة بفيروس نقص المناعة البشرية ، مثل أتازانافير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ميثوتريكسات (يستخدم لعلاج التهاب المفاصل الروماتويدي والصدفية والسرطان)&nbsp; إذا كنت تتناول الميثوتريكسات ، فقد يوقف طبيبك مؤقتًا علاج البانتروكس لأن البانتروكس يمكن أن يزيد من مستويات الميثوتريكسات في الدم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;فلوفوكسامين (يستخدم لعلاج الاكتئاب وأمراض نفسية أخرى)&nbsp; إذا كنت تتناول فلوفوكسامين فقد يقوم الطبيب بتقليل الجرعة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ريفامبيسين (لعلاج الالتهابات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;نبتة سانت جون , والتي تستخدم لعلاج الاكتئاب الخفيف.</p><p dir="RTL">يرجى إخبار طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى ، بما في ذلك الأدوية التي تم الحصول عليها بدون وصفة طبية.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">لا توجد بيانات كافية عن استخدام البانتروكس عند النساء الحوامل. تم الإبلاغ عن إفرازه في لبن الأم.</p><p dir="RTL">إذا كنت حاملاً أو مرضعة أو تعتقدين أنك حامل، أو تخططين لإنجاب طفل، استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">يجب عليك استخدام هذا الدواء ، فقط إذا اعتبر طبيبك أن الفائدة التي تعود عليك أكبر من المخاطر المحتملة على طفلك الذي لم يولد بعد أو طفلك.</p><p dir="RTL"><strong>القيادة واستعمال الآلات</strong></p><p dir="RTL">لا يؤثر تنازل عقار بانتروكس على القدرة على القيادة واستخدام الآلات أو له تأثير ضئيل.</p><p dir="RTL">إذا كنت تعاني من آثار جانبية مثل الدوخة أو اضطراب الرؤية فلا يجب عليك القيادة أو تشغيل الآلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احرص دائمًا على تناول هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL"><strong>طريقة الاستخدام</strong></p><p dir="RTL">تناول الأقراص قبل الوجبة بساعة واحدة دون مضغها أو كسرها وابتلعها كاملة مع القليل من الماء.</p><p dir="RTL">الجرعة الموصي بها هي:</p><p dir="RTL"><strong>البالغين والمراهقين 12 سنة وما فوق</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج التهاب المريء الارتجاعي</p><p dir="RTL">الجرعة المعتادة هي قرص واحد في اليوم. قد يخبرك طبيبك بزيادة إلى 2 حبة يوميا. تتراوح فترة علاج التهاب المريء الارتجاعي عادة بين 4 و 8 أسابيع. سيخبرك طبيبك بمدة تناول الدواء.</p><p dir="RTL"><strong>الكبار</strong></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>&nbsp;&nbsp;لعلاج عدوى ببكتيريا تسمى هيليكوباكتر بيلوري في المرضى الذين يعانون من قرحة الاثني عشر وقرحة المعدة بالاشتراك مع اثنين من المضادات الحيوية (علاج الاستئصال). قرص واحد ، مرتين في اليوم بالإضافة إلى قرصين من المضادات الحيوية إما من أموكسيسيلين ، كلاريثروميسين وميترونيدازول (أو تينيدازول) ، يؤخذ كل منهما مرتين في اليوم مع قرص بانتوبرازول. خذ قرص بانتوبرازول الأول قبل ساعة واحدة من الإفطار وقرص بانتوبرازول الثاني قبل ساعة واحدة من وجبة المساء. اتبع تعليمات طبيبك وتأكد من قراءة منشورات العبوة لهذه المضادات الحيوية. فترة العلاج المعتادة هي أسبوع إلى أسبوعين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج قرحة المعدة والاثني عشر. الجرعة المعتادة هي قرص واحد في اليوم. بعد التشاور مع طبيبك ، يمكن مضاعفة الجرعة. سيخبرك طبيبك بمدة تناول الدواء. عادة ما تكون فترة علاج قرحة المعدة بين 4 و 8 أسابيع. عادة ما تكون فترة علاج قرحة الاثني عشر بين 2 و 4 أسابيع.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong>لعلاج متلازمة زولينجر إليسون على المدى الطويل والحالات الأخرى التي يتم فيها إنتاج الكثير من حمض المعدة. عادة ما تكون جرعة البدء الموصى بها قرصين في اليوم. خذ قرصين 1 ساعة قبل وجبة الطعام. قد يقوم طبيبك لاحقا بتعديل الجرعة ، اعتمادا على كمية حمض المعدة التي تنتجها. إذا تم وصف أكثر من قرصين في اليوم ، يجب تناول الأقراص مرتين يوميا. إذا وصف طبيبك جرعة يومية من أكثر من أربعة أقراص في اليوم ، سيتم إخبارك بالضبط متى تتوقف عن تناول الدواء.</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل في الكلى</strong></p><p dir="RTL">إذا كنت تعاني من مشاكل في الكلى ، يجب ألا تتناول بانتروكس للقضاء على هيليكوباكتر بيلوري.</p><p dir="RTL"><strong>المرضى الذين يعانون من مشاكل في الكبد</strong></p><p dir="RTL">إذا كنت تعاني من مشاكل خطيرة في الكبد فلا يجوز تناول أكثر من قرص واحد 20 ملجرام بانتوبرازول يوميا (لهذا الغرض تتوفر أقراص تحتوي على 20 ملجرام بانتوبرازول). إذا كنت تعاني من مشاكل معتدلة أو شديدة في الكبد ، يجب ألا تتناول بانتروكس للقضاء على هيليكوباكتر بيلوري..</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين</strong></p><p dir="RTL">لا ينصح باستخدام هذه الأقراص للأطفال دون سن 12 عامًا.</p><p dir="RTL"><strong>إذا تناولت عقار بانتروكس أكثر مما ينبغي</strong></p><p dir="RTL">يجب عليك استشارة طبيبك أو الصيدلي. لا توجد أعراض معروفة للجرعة زائدة.</p><p dir="RTL"><strong>إذا نسيت تناول عقار بانتروكس</strong></p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. تناول جرعتك العادية التالية في الوقت المعتاد.</p><p dir="RTL"><strong>التوقفت عن تناول عقار بانتروكس</strong></p><p dir="RTL">لا تتوقف عن تناول هذه الأقراص دون التحدث مع طبيبك أو الصيدلي.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء اسأل طبيبك أو الصيدلي أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية يمكن أن يسبب هذا الدواء آثارًا جانبية على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>إذا شعرت بأي من الآثار الجانبية التالية فيجب التوقف عن تناول هذه الأقراص وأخبر طبيبك على الفور أو اتصل بقسم الطوارئ في أقرب مستشفى</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<strong>ردود فعل تحسسية خطيرة (نادرة الحدوث</strong>: قد تؤثر على مايصل إلى شخص من كل 1000 شخص): انتفاخ اللسان و / أو الحلق ، صعوبة في البلع ، الشرى (طفح جلدي) ، صعوبات في التنفس ، انتفاخ الوجه التحسسي (ورم كوينك / ورم وعائي عصبي) ، دوخة شديدة مع تسارع ضربات القلب وتعرق شديد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;حالات جلدية خطيرة (غير معروف معدلاتها</strong>: لا يمكن تقدير معدلاتها من البيانات المتاحة): تقرحات في الجلد وتدهور سريع لحالتك العامة ، تآكل (بما في ذلك نزيف طفيف) في العينين أو الأنف أو الفم / الشفاه أو الأعضاء التناسلية (متلازمة ستيفنز جونسون ، متلازمة ليل ، حمامى عديدة الأشكال) ، والحساسية للضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<strong>حالات خطيرة أخرى (غير معروف معدلاتها</strong>: لا يمكن تقدير معدلاتها من البيانات المتاحة): اصفرار الجلد أو بياض العين (تلف شديد لخلايا الكبد ، يرقان) أو حمى ، طفح جلدي ، وتضخم الكلى أحيانًا مع تبول مؤلم. وآلام أسفل الظهر (التهاب حاد في الكلى) مما قد يؤدي إلى فشل كلوي.</p><p dir="RTL">الآثار الجانبية الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<strong>شائعة </strong>(قد تظهر لدى ما يصل إلى شخص من كل 10 أشخاص)</p><p dir="RTL">الاورام الحميدة في المعدة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong><strong>غير شائعة </strong>(قد تظهر لدى ما يصل إلى شخص من كل 100 شخص)</p><p dir="RTL">صداع بالراس؛ دوخة؛ إسهال؛ الشعور بالغثيان والقيء. انتفاخ البطن (الريح) إمساك؛ فم جاف؛ آلام في البطن وعدم الراحة.&nbsp; طفح ، طفح جلدي ، تهيج، الشعور بالضعف أو الإرهاق أو التوعك بشكل عام ؛ اضطرابات النوم ،كسر في الورك أو الرسغ أو العمود الفقري.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong><strong>نادرة</strong> (قد تظهر لدى مايصل إلى شخص من كل 1000 شخص)</p><p dir="RTL">تشويه أو نقص كامل في حاسة التذوق ؛ اضطرابات في الرؤية مثل عدم وضوح الرؤية. طفح ، ألم في المفاصل. آلام في العضلات تغيرات الوزن ارتفاع درجة حرارة الجسم ؛ تورم في الأطراف (ورم طرفي) ؛ ردود فعل تحسسية ، اكتئاب؛ تضخم الثدي عند الذكور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<strong>نادرة جدا</strong> (قد تظهر لدى ما يصل إلى شخص من بين 10000 شخص)</p><p dir="RTL">الارتباك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<strong>غير معروف</strong> معدلاتها(لا يمكن تقدير معدلاتها من البيانات المتاحة)</p><p dir="RTL">الهلوسة والارتباك (خاصة عند المرضى الذين لديهم تاريخ من هذه الأعراض). انخفاض مستوى الصوديوم في الدم، انخفاض مستوى الماغنيسيوم في الدم (انظر القسم 2) ، الشعور بوخز ، إحساس حارق أو تنميل ، طفح جلدي ، ربما مع ألم في المفاصل.</p><p dir="RTL"><strong>الآثار الجانبية التي تم تحديدها من خلال اختبارات الدم</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;</strong><strong>غير شائعة</strong> (قد تظهر لدى ما يصل إلى شخص من كل 100 شخص) زيادة في إنزيمات الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<strong>نادرة </strong>(قد تظهر لدى حتى ما يصل إلى شخص من كل 1000 شخص)</p><p dir="RTL">زيادة في البيليروبين. زيادة مستويات الدهون في الدم. انخفاض حاد في خلايا الدم البيضاء الحبيبية المنتشرة ، مصحوبة بارتفاع درجة الحرارة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;<strong>نادر جدًا</strong> (قد يؤثر على ما يصل إلى شخص من بين 10000 شخص) انخفاض في عدد الصفائح الدموية ، مما قد يؤدي إلى نزيف أو كدمات أكثر من المعتاد ؛ انخفاض في عدد خلايا الدم البيضاء ، مما قد يؤدي إلى حدوث عدوى أكثر تكرارًا ؛ تعايش انخفاض غير طبيعي في عدد خلايا الدم الحمراء والبيضاء ، وكذلك الصفائح الدموية.</p><p><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p>إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ الطبيب أو مقدم الرعاية الصحية أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب التخزين بدرجة حرارة دون 30 درجة مئوية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيدا عن متناول الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة . يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي البانتروكس</strong></p><p dir="RTL"><strong>بانتروكس 20</strong></p><p dir="RTL">المادة الفعالة هي بانتوبرازول الصوديوم سيسكويهيدرات.</p><p dir="RTL">يحتوي كل قرص مقاوم للجهاز الهضمي على بانتوبرازول صوديوم سيسكويهيدرات ما يعادل 20 ملجرام من بانتوبرازول.</p><p dir="RTL">المكونات الأخرى هي: اللاكتوز أحادي الهيدرات ، هيدروكسي بروبيل السليلوز ، ستيرات الكالسيوم ، كربونات الصوديوم اللامائية ، كبريتات لوريل الصوديوم ، هيبروميلوز ، أكسيد الحديديك الأصفر ، بروبيلين جليكول ، ثاني أكسيد التيتانيوم ، حمض الميثاكريليك وإيثيل أكريليت كوبوليمر ، بولي إيثيل سيترات 80.</p><p dir="RTL">مكونات حبر الطباعة: طلاء شيلاك ~ 45٪ (20٪ مؤسترة) في الإيثانول ، كحول الأيزوبروبيل ، أكسيد الحديدوزوفير / أكسيد الحديد الأسود ، كحول إن بوتيل ، بروبيلين جلايكول ، هيدروكسيد الأمونيوم 28٪.</p><p dir="RTL"><strong>بانتروكس 40</strong></p><p dir="RTL">المادة الفعالة هي بانتوبرازول الصوديوم سيسكويهيدرات.</p><p dir="RTL">يحتوي كل قرص مقاوم للمعدة على بانتوبرازول صوديوم سيسكويهيدراتي ما يعادل 40 ملجرام من بانتوبرازول.</p><p dir="RTL">المكونات الأخرى هي: اللاكتوز أحادي الهيدرات ، هيدروكسي بروبيل السليلوز ، ستيرات الكالسيوم ، كربونات الصوديوم اللامائية ، كبريتات لوريل الصوديوم ، هيبروميلوز ، أكسيد الحديديك الأصفر ، بروبيلين جليكول ، ثاني أكسيد التيتانيوم ، حمض الميثاكريليك وإيثيل أكريليت كوبوليمر ، بولي إيثيل سيترات 80.</p><p dir="RTL">مكونات حبر الطباعة: طلاء شيلاك ~ 45٪ (20٪ مؤسترة) في الإيثانول ، كحول الأيزوبروبيل ، أكسيد الحديدوزوفير / أكسيد الحديد الأسود ، كحول إن بوتيل ، بروبيلين جلايكول ، هيدروكسيد الأمونيوم 28٪.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو البانتروكس؟</strong></p><p dir="RTL"><strong>بانتروكس 20</strong></p><p dir="RTL">أقراص ذات لون أصفر إلى أصفر باهت ، بيضاوية ، محدبة الوجهين ، أقراص ذات تغليف معوي مطبوع عليها &quot;H125&quot; على جانب واحد بحبر أسود وعادي على الجانب الآخر.</p><p dir="RTL"><strong>بانتروكس 40</strong></p><p dir="RTL">أقراص ذات لون أصفر إلى أصفر باهت ، بيضاوية ، محدبة الوجهين ، أقراص ذات تغليف معوي مطبوع عليها &quot;H126&quot; على جانب واحد بحبر أسود وعادي على الجانب الآخر.</p><p dir="RTL"><strong>كيف تتوفر</strong><strong>:</strong></p><p dir="RTL">تتوافر أقراص بانتروكس ٢٠ ملجرام في شرائط.</p><p dir="RTL">علبة تحتوي على 20 قرص على هيئة (2*10)، و30 قرص على هيئة (3*10)، و60 قرص على هيئة (6*10).</p><p dir="RTL">تتوافر أقراص بانتروكس ٤٠ ملجرام في شرائط.</p><p dir="RTL">علبة تحتوي على 20 قرص على هيئة (2*10)، و30 قرص على هيئة (3*10)، و60 قرص على هيئة (6*10).\</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق والمصنع</strong><strong> </strong></p><p dir="RTL"><strong>صاحب حق التسويق</strong><strong>:</strong></p><p dir="RTL"><strong>شركة أماروكس السعودية للصناعة</strong></p><p dir="RTL">شارع الجامعة ، حي الملز</p><p dir="RTL">الرياض 12629 ، المملكة العربية السعودية</p><p dir="RTL">هاتف و فاكس: 966112268850+</p><p dir="RTL"><strong>المصنع</strong><strong>: </strong></p><p dir="RTL">هتيرو لاب المحدودة - الوحدة الخامسة - الهند</p><p dir="RTL"><strong>تمت مراجعة هذه النشرة في أكتوبر 2023 ، نسخة 1</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ حول الأعراض الجانبية التي قد تحدث يرجى التواصل عبر العناوين التالية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المملكة العربية السعودية</strong><strong>:</strong></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">المركز الوطني للتيقظ الدوائي :</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: &nbsp;https://ade.sfda.gov.s</p><p dir="RTL">Please update the website in Illustrator format without changing place</p></td></tr></tbody></table><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دول الخليج العربي الأخرى</strong><strong>:</strong></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الرجاء</strong><strong> </strong><strong>الاتصال</strong><strong> </strong><strong>بالجهات</strong><strong> </strong><strong>الوطنية</strong><strong> </strong><strong>في</strong><strong> </strong><strong>كل</strong><strong> </strong><strong>دولة</strong></p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            أكتوبر 2023 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pantrox (Pantoprazole Gastro Resistance Tablets 40mg) 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each gastro-resistance tablet contains Pantoprazole sodium sesquihydrate equivalent to 40 mg of Pantoprazole 
Excipient(s) with known effect  
For full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gastro Resistance Tablet 
Yellow to pale yellow, oval, biconvex, gastro resistant tablets imprinted 'H126' on one side with black ink and plain on the other side.  

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole is indicated for use in adults and adolescents 12 years of age and above for: <strong>&nbsp;</strong></p><p>-&nbsp; Reflux oesophagitis. <strong>&nbsp;</strong></p><p>Pantoprazole is indicated in adults for: <strong>&nbsp;</strong></p><p>-&nbsp; Eradication of <em>Helicobacter pylori </em>(<em>H. pylori</em>) in combination with appropriate antibiotic therapy in patients with <em>H. pylori </em>associated ulcers. <strong>&nbsp;</strong></p><p>-&nbsp; Gastric and duodenal ulcer.</p><p>-&nbsp; Zollinger-Ellison-Syndrome and other pathological hyper secretory conditions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology <strong>&nbsp;</strong></p><p>Adults and adolescents 12 years of age and above <strong>&nbsp;</strong></p><p>Reflux oesophagitis&nbsp;</p><p>One tablet of Pantoprazole per day. In individual cases the dose may be doubled (increase to 2 tablets Pantoprazole daily) especially when there has been no response to other treatment. A 4-week period is usually required for the treatment of reflux oesophagitis. If this is not sufficient, healing will usually be achieved within a further 4 weeks.</p><p>Adults&nbsp;</p><p>Eradication of H. pylori in combination with two appropriate antibiotics&nbsp;</p><p>In H. pylori positive patients with gastric and duodenal ulcers, eradication of the germ by a combination therapy should be achieved. Considerations should be given to official local guidance (e.g. national recommendations) regarding bacterial resistance and the appropriate use and prescription of antibacterial agents. Depending upon the resistance pattern, the following combinations can be recommended for the eradication of H. pylori: a) Twice daily one tablet Pantoprazole&nbsp; + twice daily 1000 mg amoxicillin&nbsp; + twice daily 500 mg clarithromycin&nbsp;</p><p>b) Twice daily one tablet Pantoprazole&nbsp;</p><p>+ twice daily 400 - 500 mg metronidazole (or 500 mg tinidazole)&nbsp; + twice daily 250 - 500 mg clarithromycin&nbsp; c) Twice daily one tablet Pantoprazole&nbsp;</p><p>+ twice daily 1000 mg amoxicillin&nbsp;</p><p>+ twice daily 400 - 500 mg metronidazole (or 500 mg tinidazole)&nbsp;</p><p>In combination therapy for eradication of H. pylori infection, the second Pantoprazole tablet should be taken 1 hour before the evening meal. The combination therapy is implemented for 7 days in general and can be prolonged for a further 7 days to a total duration of up to two weeks. If, to ensure healing of the ulcers, further treatment with pantoprazole is indicated, the dose recommendations for duodenal and gastric ulcers should be considered.&nbsp;</p><p>If combination therapy is not an option, e.g. if the patient has tested negative for H. pylori, the following dose guidelines apply for Pantoprazole monotherapy:</p><p>Treatment of gastric ulcer&nbsp;</p><p>One tablet of Pantoprazole per day. In individual cases the dose may be doubled (increase to 2 tablets of Pantoprazole daily) especially when there has been no response to other treatment. A 4-week period is usually required for the treatment of gastric ulcers. If this is not sufficient, healing will usually be achieved within a further 4 weeks.&nbsp;</p><p>Treatment of duodenal ulcer&nbsp;</p><p>One tablet of Pantoprazole per day. In individual cases the dose may be doubled (increase to 2 tablets of Pantoprazole daily) especially when there has been no response to other treatment. A duodenal ulcer generally heals within 2 weeks. If a 2-week period of treatment is not sufficient, healing will be achieved in almost all cases within a further 2 weeks.&nbsp;</p><p>Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions&nbsp;</p><p>For the long-term management of Zollinger-Ellison-Syndrome and other pathological hyper secretory conditions patients should start their treatment with a daily dose of 80 mg (2 tablets of Pantoprazole 40 mg). Thereafter, the dose can be titrated up or down as needed using measurements of gastric acid secretion to guide. With doses above 80 mg daily, the dose should be divided and given twice daily. A temporary increase of the dose above 160 mg pantoprazole is possible but should not be applied longer than required for adequate acid control.</p><p>Treatment duration in Zollinger-Ellison syndrome and other pathological hyper secretory conditions is not limited and should be adapted according to clinical needs.&nbsp;</p><p>Patients with hepatic impairment&nbsp;</p><p>A daily dose of 20 mg pantoprazole (1 tablet of 20 mg pantoprazole) should not be exceeded in patients with severe liver impairment. Pantoprazole must not be used in combination treatment for eradication of H. pylori in patients with moderate to severe hepatic dysfunction since currently no data are available on the efficacy and safety of Pantoprazole in combination treatment of these patients (see section 4.4).&nbsp;</p><p>Patients with renal impairment&nbsp;</p><p>No dose adjustment is necessary in patients with impaired renal function. Pantoprazole must not be used in combination treatment for eradication of H. pylori in patients with impaired renal function since currently no data are available on the efficacy and safety of Pantoprazole in combination treatment for these patients (see section 5.2).&nbsp;</p><p>Older people&nbsp;</p><p>No dose adjustment is necessary in older people (see section 5.2).&nbsp; Paediatric population&nbsp;</p><p>Pantoprazole is not recommended for use in children below 12 years of age because of limited data on safety and efficacy in the age group (see section 5.2).</p><p>Method of administration&nbsp;</p><p>Oral use&nbsp;</p><p>The tablets should not be chewed or crushed, and should be swallowed whole 1 hour before a meal with some water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, substituted benzimidazoles, any of the other excipients listed in section  
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hepatic impairment&nbsp;</p><p>In patients with severe liver impairment, the liver enzymes should be monitored regularly during treatment with pantoprazole, particularly on long-term use. In the case of a rise of the liver enzymes, the treatment should be discontinued (see section 4.2).&nbsp; Combination therapy&nbsp;</p><p>In the case of combination therapy, the summaries of product characteristics of the respective medicinal products should be observed.</p><p>Gastric malignancy&nbsp;</p><p>Symptomatic response to pantoprazole may mask the symptoms of gastric malignancy and may delay diagnosis. In the presence of any alarm symptom (e. g. significant unintentional weight loss,</p><p>recurrent vomiting, dysphagia, haematemesis, anaemia or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded.&nbsp;</p><p>Further investigation is to be considered if symptoms persist despite adequate treatment.&nbsp;</p><p>Co-administration with HIV protease inhibitors&nbsp;</p><p>Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir, due to significant reduction in their bioavailability (see section 4.5).&nbsp;</p><p>Influence on vitamin B12 absorption&nbsp;</p><p>In patients with Zollinger-Ellison syndrome and other pathological hyper secretory conditions requiring long-term treatment, pantoprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy or if respective clinical symptoms are observed.&nbsp;</p><p>Long term treatment&nbsp;</p><p>In long-term treatment, especially when exceeding a treatment period of 1 year, patients should be kept under regular surveillance.&nbsp;</p><p>Gastrointestinal infections caused by bacteria&nbsp;</p><p>Treatment with Pantoprazole may lead to a slightly increased risk of gastrointestinal infections caused by bacteria such as Salmonella and Campylobacter or C. difficile.&nbsp;</p><p>Hypomagnesaemia&nbsp;</p><p>Severe hypomagnesaemia has been reported in patients treated with PPIs like pantoprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or medicinal products that may cause hypomagnesaemia (e.g.&nbsp; diuretics), health care professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.&nbsp;</p><p>Bone fractures&nbsp;</p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in older people or in the presence of other recognised risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10&ndash;40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.&nbsp;</p><p>Sub-acute cutaneous lupus erythematosus (SCLE)&nbsp;</p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the healthcare professional should consider stopping Pantoprazole. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.&nbsp;</p><p>Interference with Laboratory Tests&nbsp;</p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, Pantoprazole treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Medicinal products with pH-Dependent Absorption Pharmacokinetics&nbsp;</p><p>Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with the absorption of other medicinal products where gastric pH is an important determinant of oral availability, e.g. some azole antifungals such as ketoconazole, itraconazole, posaconazole and other medicine such as erlotinib.&nbsp; <u>HIV protease inhibtiors</u>&nbsp;</p><p>Co-administration of pantoprazole is not recommended with HIV protease inhibitors for which absorption is dependent on acidic intragastric pH such as atazanavir due to significant reduction in their bioavailability (see section 4.4). If the combination of HIV protease inhibitors with a proton pump inhibitor is judged unavoidable, close clinical monitoring (e.g. virus load) is recommended. A pantoprazole dose of 20 mg per day should not be exceeded. Dosage of the HIV protease inhibitors may need to be adjusted.&nbsp;</p><p>Coumarin anticoagulants (phenprocoumon or warfarin)&nbsp;</p><p>Co-administration of pantoprazole with warfarin or phenprocoumon did not affect the pharmacokinetics of warfarin, phenprocoumon or INR. However, there have been reports of increased INR and prothrombin time in patients receiving PPIs and warfarin or phenprocoumon concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding, and even death. Patients treated with pantoprazole and warfarin or phenprocoumon may need to be monitored for increase in INR and prothrombin time.&nbsp;</p><p>Methotrexate&nbsp;</p><p>Concomitant use of high dose methotrexate (e.g. 300 mg) and proton-pump inhibitors has been reported to increase methotrexate levels in some patients. Therefore, in settings where high-dose methotrexate is used, for example cancer and psoriasis, a temporary withdrawal of pantoprazole may need to be considered.&nbsp;</p><p>Other interactions studies&nbsp;</p><p>Pantoprazole is extensively metabolized in the liver via the cytochrome P450 enzyme system. The main metabolic pathway is demethylation by CYP2C19 and other metabolic pathways include oxidation by CYP3A4. Interaction studies with medicinal products also metabolized with these pathways, like carbamazepine, diazepam, glibenclamide, nifedipine, and an oral contraceptive containing levonorgestrel and ethinyl oestradiol, did not reveal clinically significant interactions.</p><p>An interaction of pantoprazole with other medicinal products or compounds, which are metabolized using the same enzyme system, cannot be excluded.&nbsp;</p><p>Results from a range of interaction studies demonstrate that pantoprazole does not affect the metabolism of active substances metabolised by CYP1A2 (such as caffeine, theophylline), CYP2C9 (such as piroxicam, diclofenac, naproxen), CYP2D6 (such as metoprolol), CYP2E1 (such as ethanol), or does not interfere with p-glycoprotein related absorption of digoxin.&nbsp;</p><p>There were no interactions with concomitantly administered antacids.&nbsp;</p><p>Interaction studies have also been performed by concomitantly administering pantoprazole with the respective antibiotics (clarithromycin, metronidazole, amoxicillin). No clinically relevant interactions were found.&nbsp;</p><p>Medicinal products that inhibit or induce CYP2C19:&nbsp;</p><p>Inhibitors of CYP2C19 such as fluvoxamine could increase the systemic exposure of pantoprazole. A dose reduction may be considered for patients treated long-term with high doses of pantoprazole, or those with hepatic impairment.&nbsp;</p><p>Enzyme inducers affecting CYP2C19 and CYP3A4 such as rifampicin and St John&acute;s wort (Hypericum perforatum) may reduce the plasma concentrations of PPIs that are metabolized through these enzyme systems.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy&nbsp;</p><p>A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicate no malformative or feto/ neonatal toxicity of Pantoprazole.&nbsp;</p><p>Animal studies have shown reproductive toxicity (see section 5.3).&nbsp;</p><p>As a precautionary measure, it is preferable to avoid the use of Pantoprazole during pregnancy.&nbsp;</p><p>Breast-feeding&nbsp;</p><p>Animal studies have shown excretion of pantoprazole in breast milk. There is insufficient information on the excretion of pantoprazole in human milk but excretion into human milk has been reported. A risk to the newborns/infants cannot be excluded. Therefore, a decision on whether to discontinue breast-feeding or to discontinue/abstain from Pantoprazole therapy taking into account the benefit of breast-feeding for the child, and the benefit of Pantoprazole therapy for the woman.&nbsp;</p><p>Fertility&nbsp;</p><p>There was no evidence of impaired fertility following the administration of pantoprazole in animal studies (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole has no or negligible influence on the ability to drive and use machines.&nbsp;</p><p>Adverse drug reactions, such as dizziness and visual disturbances may occur (see section 4.8). If affected, patients should not drive or operate machines</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Approximately 5 % of patients can be expected to experience adverse drug reactions (ADRs). The most commonly reported ADRs are diarrhoea and headache, both occurring in approximately 1 % of patients.&nbsp;</p><p>The table below lists adverse reactions reported with pantoprazole, ranked under the following frequency classification:&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_17555" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:489pt;height:32.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="652" height="43" alt="" vspace="0" hspace="0" border="0" style="width:652px;height:43px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/Pc/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /></p><p>data).&nbsp;</p><p>For all adverse reactions reported from post-marketing experience, it is not possible to apply any Adverse Reaction frequency and therefore they are mentioned with a &ldquo;not known&rdquo; frequency.&nbsp; Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.&nbsp; Table 1. Adverse reactions with pantoprazole in clinical trials and post-marketing experience</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Common</strong></p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Uncommon</strong></p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Rare</strong></p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Very rare</strong></p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Not known</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>System&nbsp;&nbsp;&nbsp; Organ Class</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and lymphatic system</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Agranulocytosis</p></td><td style="vertical-align:top"><p>Thrombocytopenia; Leukopenia;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancytopenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Immune&nbsp;&nbsp; system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity (including anaphylactic reactions&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and anaphylactic shock)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Common</strong></p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Uncommon</strong></p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Rare</strong></p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Very rare</strong></p><p>&nbsp;</p></td><td rowspan="2" style="vertical-align:top"><p><strong>Not known</strong></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>System&nbsp;&nbsp;&nbsp; Organ Class</strong></p></td></tr><tr><td style="vertical-align:top"><p>Metabolism&nbsp;&nbsp; and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperlipidaemias and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lipid increases (triglycerides, cholesterol);</p><p>Weight changes</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyponatraemia;</p><p>Hypomagnesaemia</p><p>(see&nbsp; section&nbsp; 4.4);</p><p>Hypocalcaemia <sup>(1)</sup>;</p><p>Hypokalaemia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Sleep disorders</p></td><td style="vertical-align:top"><p>Depression&nbsp;&nbsp; (and all aggravations)</p></td><td style="vertical-align:top"><p>Disorientation (and all aggravations)</p></td><td style="vertical-align:top"><p>Hallucination;</p><p>Confusion</p><p>(especially in pre- disposed&nbsp;&nbsp; patients, as&nbsp;&nbsp;&nbsp; well&nbsp;&nbsp;&nbsp; as&nbsp;&nbsp;&nbsp; the aggravation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of these symptoms in case&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; preexistence)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous&nbsp;&nbsp; system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache; Dizziness</p></td><td style="vertical-align:top"><p>Taste disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Disturbances in vision / blurred vision</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Fundic&nbsp; gland polyps (benign)</p></td><td style="vertical-align:top"><p>Diarrhoea;</p><p>Nausea&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; / vomiting; Abdominal distension&nbsp; and bloating; Constipation;</p><p>Dry&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth;</p><p>Abdominal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Microscopic</p><p>colitis</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>pain&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and discomfort</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver enzymes increased (transaminases, &gamma;-GT)</p></td><td style="vertical-align:top"><p>Bilirubin increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatocellular injury;&nbsp;&nbsp;&nbsp; Jaundice; Hepatocellular failure</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; / exanthema&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; / eruption; Pruritus</p></td><td style="vertical-align:top"><p>Urticaria;</p><p>Angioedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens-Johnson syndrome;&nbsp;&nbsp;&nbsp;&nbsp; Lyell syndrome; Erythema multiforme; Photosensitivity; Sub-acute cutaneous&nbsp;&nbsp;&nbsp;&nbsp; lupus erythematosus (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and&nbsp;&nbsp;&nbsp; connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fracture of the hip, wrist or spine (see</p><p>section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;Arthralgia;</p><p>&nbsp;Myalgia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Muscle spasm <sup>(2)</sup></p></td></tr><tr><td style="vertical-align:top"><p>Renal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interstitial nephritis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (with possible</p><p>progression&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to renal failure)</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive</p><p>system&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gynaecomastia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and</p><p>administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthenia, fatigue&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and malaise</p></td><td style="vertical-align:top"><p>Body temperature increased; Oedema</p><p>peripheral</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>1.&nbsp; Hypocalcemia in association with hypomagnesemia</p><p>2.&nbsp; Muscle spasm as a consequence of electrolyte disturbance<u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medical product.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no known symptoms of overdose in man.&nbsp;</p><p>Systemic exposure with up to 240 mg administered intravenously over 2 minutes, were well tolerated.&nbsp;</p><p>As pantoprazole is extensively protein bound, it is not readily dialyzable</p><p>In the case of an overdose with clinical signs of intoxication, apart from symptomatic and supportive treatment, no specific therapeutic recommendations can be made.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Proton pump inhibitors, ATC code: A02BC02&nbsp;</p><p><u>Mechanism of action</u>&nbsp;</p><p>Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific blockade of the proton pumps of the parietal cells.&nbsp;</p><p>Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it inhibits the H+, K+-ATPase enzyme, i.e. the final stage in the production of hydrochloric acid in the stomach. The inhibition is dose-dependent and affects both basal and stimulated acid secretion. In most patients, freedom from symptoms is achieved within 2 weeks. As with other proton pump inhibitors and H2 receptor inhibitors, treatment with pantoprazole reduces acidity in the stomach and thereby increases gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible. Since pantoprazole binds to the enzyme distal to the cell receptor level, it can inhibit hydrochloric acid secretion independently of stimulation by other substances (acetylcholine, histamine, gastrin). The effect is the same whether the product is given orally or intravenously.&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>The fasting gastrin values increase under pantoprazole. On short-term use, in most cases they do not exceed the upper limit of normal. During long-term treatment, gastrin levels double in most cases. An excessive increase, however, occurs only in isolated cases. As a result, a mild to moderate increase in the number of specific endocrine (ECL) cells in the stomach is observed in a minority of cases during long-term treatment (simple to adenomatoid hyperplasia). However, according to the studies conducted so far, the formation of carcinoid precursors (atypical hyperplasia) or gastric carcinoids as were found in animal experiments (see section 5.3) have not been observed in humans.&nbsp;</p><p>An influence of a long term treatment with pantoprazole exceeding one year cannot be completely ruled out on endocrine parameters of the thyroid according to results in animal studies.&nbsp;</p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations for neuroendocrine tumours.&nbsp;</p><p>Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pantoprazole is rapidly absorbed and the maximal plasma concentration is achieved even after one single 40 mg oral dose. On average at about 2.5 h p.a. the maximum serum concentrations of about 2</p><p>- 3 &mu;g/ml are achieved, and these values remain constant after multiple administration. &nbsp;</p><p>Pharmacokinetics does not vary after single or repeated administration. In the dose range of 10 to 80 mg, the plasma kinetics of pantoprazole are linear after both oral and intravenous administration.&nbsp;</p><p>The absolute bioavailability from the tablet was found to be about 77 %. Concomitant intake of food had no influence on AUC, maximum serum concentration and thus bioavailability. Only the variability of the lag-time will be increased by concomitant food intake.&nbsp; <u>Distribution</u></p><p>Pantoprazole&#39;s serum protein binding is about 98 %. Volume of distribution is about 0.15 l/kg.</p><p><u>Biotransformation</u>&nbsp;</p><p>The substance is almost exclusively metabolized in the liver. The main metabolic pathway is demethylation by CYP2C19 with subsequent sulphate conjugation; other metabolic pathway includes oxidation by CYP3A4.&nbsp; <u>Elimination</u>&nbsp;</p><p>Terminal half-life is about 1 hour and clearance is about 0.1 l/h/kg. There were a few cases of subjects with delayed elimination. Because of the specific binding of pantoprazole to the proton pumps of the parietal cell the elimination half-life does not correlate with the much longer duration of action (inhibition of acid secretion).&nbsp;</p><p>Renal elimination represents the major route of excretion (about 80 %) for the metabolites of pantoprazole, the rest is excreted with the faeces. The main metabolite in both the serum and urine is desmethylpantoprazole which is conjugated with sulphate. The half-life of the main metabolite (about 1.5 hours) is not much longer than that of pantoprazole.&nbsp;</p><p><u>Special populations</u>&nbsp;</p><p>Poor metabolisers&nbsp;</p><p>Approximately 3 % of the European population lack a functional CYP2C19 enzyme and are called poor metabolisers. In these individuals the metabolism of pantoprazole is probably mainly catalysed by CYP3A4. After a single-dose administration of 40 mg pantoprazole, the mean area under the plasma concentration-time curve was approximately 6 times higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were increased by about 60 %. These findings have no implications for the posology of pantoprazole.&nbsp; Renal impairment&nbsp;</p><p>No dose reduction is recommended when pantoprazole is administered to patients with impaired renal function (including dialysis patients). As with healthy subjects, pantoprazole&#39;s half-life is short. Only very small amounts of pantoprazole are dialyzed. Although the main metabolite has a moderately delayed half-life (2 - 3 h), excretion is still rapid and thus accumulation does not occur.</p><p>Hepatic impairment&nbsp;</p><p>Although for patients with liver cirrhosis (classes A and B according to Child) the half-life values increased to between 7 and 9 h and the AUC values increased by a factor of 5 - 7, the maximum serum concentration only increased slightly by a factor of 1.5 compared with healthy subjects.&nbsp;</p><p>Older people&nbsp;</p><p>A slight increase in AUC and C<sub>max </sub>in elderly volunteers compared with younger counterparts is also not clinically relevant.&nbsp; Paediatric population&nbsp;</p><p>Following administration of single oral doses of 20 or 40 mg pantoprazole to children aged 5 - 16 years AUC and C<sub>max</sub> were in the range of corresponding values in adults.&nbsp;</p><p>Following administration of single i.v. doses of 0.8 or 1.6 mg/kg pantoprazole to children aged 2 - 16</p><p>years there was no significant association between pantoprazole clearance and age or weight. AUC and volume of distribution were in accordance with data from adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard to humans based on conventional studies of safety pharmacology, repeated dose toxicity and genotoxicity.&nbsp;</p><p>In the two-year carcinogenicity studies in rats neuroendocrine neoplasms were found. In addition, squamous cell papillomas were found in the fore stomach of rats. The mechanism leading to the formation of gastric carcinoids by substituted benzimidazoles has been carefully investigated and allows the conclusion that it is a secondary reaction to the massively elevated serum gastrin levels occurring in the rat during chronic high-dose treatment. In the two-year rodent studies an increased number of liver tumours was observed in rats and in female mice and was interpreted as being due to pantoprazole&#39;s high metabolic rate in the liver.&nbsp;</p><p>A slight increase of neoplastic changes of the thyroid was observed in the group of rats receiving the highest dose (200 mg/kg). The occurrence of these neoplasms is associated with the pantoprazoleinduced changes in the breakdown of thyroxine in the rat liver. As the therapeutic dose in man is low, no harmful effects on the thyroid glands are expected.&nbsp;</p><p>In a peri-postnatal rat reproduction study designed to assess bone development, signs of offspring toxicity (mortality, lower mean body weight, lower mean body weight gain and reduced bone growth) were observed at exposures (C<sub>max</sub>) approximately 2x the human clinical exposure. By the end of the recovery phase, bone parameters were similar across groups and body weights were also trending toward reversibility after a drug-free recovery period. The increased mortality has only been reported in pre-weaning rat pups (up to 21 days age) which is estimated to correspond to infants up to the age of 2 years old. The relevance of this finding to the paediatric population is unclear. A previous peri-postnatal study in rats at slightly lower doses found no adverse effects at 3 mg/kg compared with a low dose of 5 mg/kg in this study.&nbsp;</p><p>Investigations revealed no evidence of impaired fertility or teratogenic effects.&nbsp;</p><p>Penetration of the placenta was investigated in the rat and was found to increase with advanced gestation. As a result, concentration of pantoprazole in the foetus is increased shortly before birth.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate, Hydroxypropyl cellulose, Calcium Stearate, Sodium carbonate anhydrous,</p><p>Sodium lauryl sulphate, Hypromellose, Ferric oxide yellow, Propylene glycol, Titanium dioxide, Methacrylic acid &ndash; Ethylacrylate copolymer (1:1) dispersion 30%, Triethyl citrate, Polysorbate80 and purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company Al Jamiah Street, Al Malaz District Riyadh 12629, Saudi Arabia.
Tel & Fax: +966 11 226 8850.
Manufacturer
Hetero Labs Limited Unit V, India.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NA
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>